Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways
- PMID: 31412267
- DOI: 10.1016/j.ejphar.2019.172594
Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways
Abstract
Glucagon like peptide-1 (GLP-1) promotes postprandial insulin secretion. Liraglutide, a full agonist of the GLP-1 receptor, reduces body weight, improve insulin sensitivity, and alleviate Non Alcoholic Fatty Liver Disease (NAFLD). However, the underlying mechanisms remain unclear. This study aims to explore the underlying mechanisms and cell signaling pathways involved in the anti-obesity and anti-inflammatory effects of liraglutide. Mice were fed a high fat high sucrose diet to induce diabetes, diabetic mice were divided into two groups and injected with liraglutide or vehicle for 14 days. Liraglutide treatment improved insulin sensitivity, accompanied with reduced expression of the phosphorylated Acetyl-CoA carboxylase-2 (ACC2) and upregulation of long chain acyl CoA dehydrogenase (LCAD) in insulin sensitive tissues. Furthermore, liraglutide induced adenosine monophosphate-activated protein kinase-α (AMPK-α) and Sirtuin-1(Sirt-1) protein expression in liver and perigonadal fat. Liraglutide induced elevation of fatty acid oxidation in these tissues may be mediated through the AMPK-Sirt-1 cell signaling pathway. In addition, liraglutide induced brown adipocyte differentiation in skeletal muscle, including induction of uncoupling protein-1 (UCP-1) and PR-domain-containing-16 (PRDM-16) protein in association with induction of SIRT-1. Importantly, liraglutide displayed anti-inflammation effect. Specifically, liraglutide led to a significant reduction in circulating interleukin-1 β (IL-1 β) and interleukin-6 (IL-6) as well as hepatic IL-1 β and IL-6 content. The expression of inducible nitric oxide synthase (iNOS-1) and cyclooxygenase-2 (COX-2) in insulin sensitive tissues was also reduced following liraglutide treatment. In conclusion, liraglutide improves insulin sensitivity through multiple pathways resulting in reduction of inflammation, elevation of fatty acid oxidation, and induction of adaptive thermogenesis.
Keywords: Adipocyte; Insulin resistance; Liraglutide; Metabolism; Obesity.
Copyright © 2019 Elsevier B.V. All rights reserved.
Similar articles
-
Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.Endocrine. 2019 May;64(2):271-283. doi: 10.1007/s12020-018-1826-7. Epub 2018 Dec 9. Endocrine. 2019. PMID: 30535743
-
Cooperative role of the glucagon-like peptide-1 receptor and β3-adrenergic-mediated signalling on fat mass reduction through the downregulation of PKA/AKT/AMPK signalling in the adipose tissue and muscle of rats.Acta Physiol (Oxf). 2018 Apr;222(4):e13008. doi: 10.1111/apha.13008. Epub 2017 Dec 19. Acta Physiol (Oxf). 2018. PMID: 29193738
-
FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis.Mol Metab. 2017 Apr 5;6(6):471-481. doi: 10.1016/j.molmet.2017.04.001. eCollection 2017 Jun. Mol Metab. 2017. PMID: 28580278 Free PMC article.
-
Liraglutide regulates lipid metabolism via FGF21- LKB1- AMPK- ACC1 pathway in white adipose tissues and macrophage of type 2 diabetic mice.Biochem Biophys Res Commun. 2021 Apr 9;548:120-126. doi: 10.1016/j.bbrc.2021.02.065. Epub 2021 Feb 25. Biochem Biophys Res Commun. 2021. PMID: 33640604
-
Inflammation in obesity is the common link between defects in fatty acid metabolism and insulin resistance.Cell Cycle. 2007 Apr 15;6(8):888-94. doi: 10.4161/cc.6.8.4135. Epub 2007 Apr 11. Cell Cycle. 2007. PMID: 17438370 Review.
Cited by
-
Progress in the contrary effects of glucagon-like peptide-1 and chemerin on obesity development.Exp Biol Med (Maywood). 2023 Nov;248(22):2020-2029. doi: 10.1177/15353702231214270. Epub 2023 Dec 6. Exp Biol Med (Maywood). 2023. PMID: 38058030 Review.
-
The Novel Tetra-Specific Drug C-192, Conjugated Using UniStac, Alleviates Non-Alcoholic Steatohepatitis in an MCD Diet-Induced Mouse Model.Pharmaceuticals (Basel). 2023 Nov 13;16(11):1601. doi: 10.3390/ph16111601. Pharmaceuticals (Basel). 2023. PMID: 38004466 Free PMC article.
-
Recent advancements in pharmacological strategies to modulate energy balance for combating obesity.RSC Med Chem. 2023 Jun 14;14(8):1429-1445. doi: 10.1039/d3md00107e. eCollection 2023 Aug 16. RSC Med Chem. 2023. PMID: 37593583 Review.
-
Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?J Endocrinol Invest. 2023 Nov;46(11):2213-2236. doi: 10.1007/s40618-023-02125-0. Epub 2023 Jun 28. J Endocrinol Invest. 2023. PMID: 37378828 Free PMC article. Review.
-
Glp-1 Receptor Agonists Regulate the Progression of Diabetes Mellitus Complicated with Fatty Liver by Down-regulating the Expression of Genes Related to Lipid Metabolism.Appl Biochem Biotechnol. 2023 Aug;195(8):5238-5251. doi: 10.1007/s12010-023-04505-x. Epub 2023 May 4. Appl Biochem Biotechnol. 2023. PMID: 37140780
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
